Cadent Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Cadent Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,468	Closed	-$222K	–	134
2023 Q2	$222K	Buy	3,468 +29	+0.8%	+$1.95K	0.13%	119
2023 Q1	$238K	Buy	3,439 +125	+4%	+$8.82K	0.11%	109
2022 Q4	$238K	Buy	3,314 +23	+0.7%	+$1.73K	0.12%	106
2022 Q3	$234K	Buy	3,291 +23	+0.7%	+$1.67K	0.13%	92
2022 Q2	$252K	Sell	3,268 -64	-2%	-$4.87K	0.14%	89
2022 Q1	$243K	Buy	+3,332	New	+$224K	0.11%	114
2021 Q3	–	Sell	-2,998	Closed	-$200K	–	131
2021 Q2	$200K	Sell	2,998 -326	-10%	-$21.3K	0.08%	137
2021 Q1	$210K	Buy	+3,324	New	+$207K	0.09%	124

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cadent Capital Advisors's BMY Position: Q3 2023 in Review

Cadent Capital Advisors sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 3,468 shares — an estimated $222K sold.

Cadent Capital Advisors first reported a position in BMY in Q1 2021 and held it in 8 quarters. The position peaked at $252K in Q2 2022. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

Cadent Capital Advisors reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
Cadent Capital Advisors sold 3,468 Bristol-Myers Squibb shares in Q3 2023, an estimated $222K.
Cadent Capital Advisors first reported a position in Bristol-Myers Squibb in Q1 2021 and held it in 8 quarters.
Cadent Capital Advisors's Bristol-Myers Squibb position peaked at $252K in Q2 2022.
2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Cadent Capital Advisors's 13F filing for Q3 2023, filed 10 Oct 2023.